16 [16] A. A˚berg, L. Westbom, and B. Ka¨lle´n, “Congenital malforma- tions among infants whose mothers had gestational diabetes or preexisting diabetes,” Early Human Development, vol. 61, no. 2, pp. 85–95, 2001. [17] A. A. Rimm, A. C. Katayama, and K. P. Katayama, “A meta-analysis of the impact of IVF and ICSI on major malformations after adjusting for the eﬀect of subfertility,” Journal of Assisted Reproduction and Genetics, vol. 28, no. 8, pp. 699–705, 2011. [18] B. Ka¨lle´n, O. Finnstro¨m, K. G. Nygren, and P. O. Olausson, “In vitro fertilization (IVF) in Sweden: risk for congenital malformations after diﬀerent IVF methods,” Birth Defects Research Part A, vol. 73, no. 3, pp. 162–169, 2005. [19] K. Ka¨lle´n, “Maternal smoking and orofacial clefts,” Cleft Palate-Craniofacial Journal, vol. 34, no. 1, pp. 11–16, 1997. [20] E. J. Lammer, G. M. Shaw, D. M. Iovannisci, and R. H. Finnell, “Maternal smoking, genetic variation of glutathione S-transferases, and risk for orofacial clefts,” Epidemiology, vol. 16, no. 5, pp. 698–701, 2005. [21] J. M. Elwood, J. Little, and H. Elwood, Epidemiology and Control of Neural Tube Defects, vol. 20 of Monographs in Epidemiology and Biostatistics, Oxford University Press, New York, NY, USA, 1992. [22] K Ka¨lle´n, “Fo¨rlossningsresultat bland invandrarkvinnor i Sverige. (Delivery results among immigrant women in Swe- den),” EpC Report 1998:1. National Board of Health and Welfare. [23] K. S. Au, A. Ashley-Koch, and H. Northrup, “Epidemiologic and genetic aspects of spina biﬁda and other neural tube defects,” Developmental Disabilities Research Reviews, vol. 16, no. 1, pp. 6–15, 2010. [24] M. Reis and B. Ka¨lle´n, “Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data,” Psychological Medicine, vol. 40, no. 10, pp. 1723–1733, 2010. [25] T. F. Oberlander, W. Warburton, S. Misri, W. Riggs, J. Agha- janian, and C. Hertzman, “Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data,” Birth Defects Research Part B, vol. 83, no. 1, pp. 68–76, 2008. [26] B. Ka¨lle´n and I. Mottet, “Delivery outcome after the use of meclozine in early pregnancy,” European Journal of Epidemi- ology, vol. 18, no. 7, pp. 665–669, 2003. [27] B. Ka¨lle´n, O. Finnstro¨m, A. Lindam, E. Nilsson, K. G. Nygren, and P. O. Olausson, “Selected neonatal outcomes in dizygotic twins after IVF versus non-IVF pregnancies,” BJOG, vol. 117, no. 6, pp. 676–682, 2010. [28] S. R. Meadow, “Congenital abnormalities and anticonvulsant drugs,” Proceedings of the Royal Society of Medicine, vol. 63, no. 1, pp. 48–49, 1970. [29] B. A. J. Ka¨lle´n and P. O. Olausson, “Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations,” Birth Defects Research Part A, vol. 79, no. 4, pp. 301–308, 2007. [30] H. Malm, M. Artama, M. Gissler, and A. Ritvanen, “Selective serotonin reuptake inhibitors and risk for major congenital anomalies,” Obstetrics and Gynecology, vol. 118, no. 1, pp. 111– 120, 2011. [31] W. O. Cooper, S. Hernandez-Diaz, P. G. Arbogast et al., “Major congenital malformations after ﬁrst-trimester exposure to ACE inhibitors,” New England Journal of Medicine, vol. 354, no. 23, pp. 2443–2451, 2006. [32] R. Lennesta˚l, P. Otterblad Olausson, and B. Ka¨lle´n, “Maternal use of antihypertensive drugs in early pregnancy and delivery Obstetrics and Gynecology International outcome, notably the presence of congenital heart defects in the infants,” European Journal of Clinical Pharmacology, vol. 65, no. 6, pp. 615–625, 2009. [33] B. A. J. Ka¨lle´n, P. O. Olausson, and B. R. Danielsson, “Is erythromycin therapy teratogenic in humans?” Reproductive Toxicology, vol. 20, no. 2, pp. 209–214, 2005. [34] I. Mylonas, “Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration,” Archives of Gyne- cology and Obstetrics, vol. 283, no. 1, pp. 7–18, 2011. [35] S. S. Hashmi, M. S. Gallaway, D. K. Waller, P. H. Langlois, and J. T. Hecht, “Maternal fever during early pregnancy and the risk of oral clefts,” Birth Defects Research Part A, vol. 88, no. 3, pp. 186–194, 2010. [36] I. Borthen, M. G. Eide, A. K. Daltveit, and N. E. Gilhus, “Obstetric outcome in women with epilepsy: a hospital-based, retrospective study,” BJOG, vol. 118, no. 8, pp. 956–965, 2011. [37] T. F. Oberlander, W. Warburton, S. Misri, J. Aghajanian, and C. Hertzman, “Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data,” Archives of General Psychiatry, vol. 63, no. 8, pp. 898– 906, 2006. [38] A. J. B. Ka¨lle´n, O. O. Finnstro¨m, A. P. Lindam, E. M. E. Nilsson, K.-G. Nygren, and P. M. Otterblad Olausson, “Is there an increased risk for drug treated attention deﬁcit/hyperactivity disorder in children born after in vitro fertilization?” European Journal of Paediatric Neurology, vol. 15, no. 3, pp. 247–253, 2011. [39] V. S. Knopik, “Maternal smoking during pregnancy and child outcomes: real or spurious eﬀect?” Developmental Neuropsy- chology, vol. 34, no. 1, pp. 1–36, 2009. [40] A. Thapar, F. Rice, D. Hay et al., “Prenatal smoking might not cause attention-deﬁcit/hyperactivity disorder: evidence from a novel design,” Biological Psychiatry, vol. 66, no. 8, pp. 722–727, 2009.